How Fear of COVID-19 Can Affect Treatment Choices for Anaplastic Large Cell Lymphomas ALK+ Therapy: A Case Report.

Antonello Sica Caterina SagnelliBeniamino CasaleGino SvaneraMassimiliano CretaArmando CalogeroRenato FrancoEvangelista SagnelliAndrea Ronchi

Published in: Healthcare (Basel, Switzerland) (2021)

The response to crizotinib was optimal since no adverse event occurred, and CT-PET scans persisted negative; this drug has proved to be a valid bridge to allo-SCT.